Akero Therapeutics upgraded by BofA Securities with a new price target
$AKRO
Biotechnology: Pharmaceutical Preparations
Health Care
BofA Securities upgraded Akero Therapeutics from Neutral to Buy and set a new price target of $63.00 from $35.00 previously